A phase 3 study conducted together with Ionis Pharmaceuticals shows that the drug Wainua did not meet its goals in treating heart problems in patients suffering from the rare transthyretin amyloidosis - also known as Skellefte disease.
Wainua injections are already used to treat problems related to the disease, which damages nerves and organs through misfolded proteins.
